There is no cure for Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis (ALS). No treatment can stop or reverse the progressive loss of motor neurons that defines the condition. The average survival from symptom onset ranges from 2 to 5 years, with a median of about 2.5 years from the time symptoms first appear. What does exist are treatments that can modestly slow progression, ease symptoms, and extend life by months rather than years.
Why ALS Is So Difficult to Cure
ALS destroys the nerve cells that control voluntary movement, the motor neurons in the brain and spinal cord. As these neurons die, the muscles they control weaken, waste away, and eventually stop working entirely. What makes the disease so resistant to treatment is that it doesn’t have a single cause. Instead, multiple overlapping processes drive the damage: toxic buildup of the brain’s main signaling chemical (glutamate), oxidative stress that harms cells, malfunctioning energy factories inside neurons, abnormal protein clumping, faulty transport systems within nerve fibers, and chronic inflammation.
Three competing theories attempt to explain how the degeneration spreads. One proposes it starts in the brain and travels downward along nerve pathways. Another suggests it begins at the muscles or the junctions where nerves meet muscles, then works backward into the spinal cord. A third theory holds that upper and lower motor neurons degenerate independently. The reality may involve elements of all three, and this complexity is a core reason why a single drug can’t simply switch the disease off.
Treatments Currently Available
Only a small number of FDA-approved medications exist for ALS, and none comes close to a cure. The oldest and most established is riluzole, a drug that reduces glutamate activity in the brain to protect motor neurons from overstimulation. In clinical trials, riluzole extended survival by an average of about 3 months. That’s a real but modest benefit, and it remains the baseline treatment most patients receive.
Edaravone (sold as Radicava) works differently, acting as a scavenger that neutralizes harmful molecules called free radicals before they can damage motor neurons through oxidative stress. It’s given as an infusion or taken orally, and its effects on slowing functional decline have been measured in specific patient populations.
One drug that was previously available, Relyvrio, had its FDA approval formally withdrawn in August 2025. It was originally approved based on a small early trial, but a larger Phase 3 study failed to meet its primary or secondary goals, showing the drug did not provide the expected benefit. The manufacturer voluntarily requested withdrawal, and distribution is no longer legal.
A New Approach for a Genetic Subtype
The most significant recent advance targets a specific genetic form of the disease. About 2% of ALS cases involve mutations in a gene called SOD1, which produces a protein that becomes toxic to motor neurons. In 2023, the FDA approved tofersen (Qalsody), a drug designed to intercept the genetic instructions cells use to build that toxic protein, effectively reducing how much SOD1 protein the body makes.
Tofersen doesn’t work for the vast majority of ALS patients, only those with a confirmed SOD1 mutation. Its approval was based on reductions in a blood marker of nerve damage rather than on clear improvements in physical function during the trial period. That’s an important distinction: it showed biological evidence that nerve injury was slowing, but patients didn’t demonstrate statistically significant gains on standard measures of daily function during the study’s 28-week window. Still, it represents the first treatment aimed at an underlying genetic cause of ALS rather than downstream symptoms.
Gene Therapies in Development
The approval of tofersen opened a door. At least five similar drugs, all antisense oligonucleotides that block harmful genetic instructions, are now in clinical trials for ALS. One of the most closely watched targets mutations in a gene called FUS. The trial, known as FUSION, is testing a drug called jacifusen delivered directly into the spinal fluid, with results still pending.
Beyond these targeted drugs, researchers are exploring CRISPR gene editing, the tool that allows scientists to precisely cut and modify DNA sequences. While CRISPR-based therapies are further along in blood cancers, early work suggests potential applications in ALS, particularly for the roughly 10 to 15% of cases linked to known genetic mutations. For the remaining 85 to 90% of cases, which arise without a clear inherited cause, gene therapy is far less straightforward because there’s no single gene to target.
Why Multidisciplinary Care Matters Now
In the absence of a cure, the care model surrounding a patient has a measurable impact on how long and how well they live. A Spanish study comparing ALS patients treated in a standard setting versus a coordinated multidisciplinary clinic found that median survival increased from 34 months to 40 months with the team-based approach. For patients whose disease began with speech and swallowing difficulties (bulbar onset, which typically carries a worse prognosis), the benefit was even more striking: survival jumped from 24 to 34 months.
These clinics typically bring neurologists, respiratory therapists, physical therapists, speech pathologists, nutritionists, and mental health professionals together in a single visit. The advantage isn’t just convenience. Coordinated teams catch problems earlier, initiate breathing support sooner, manage nutrition before weight loss accelerates, and connect patients and caregivers with psychological support. There’s also evidence that this model improves quality of life, not just length of it. Fewer unnecessary hospitalizations, better communication with primary care, and earlier access to palliative care all contribute.
How ALS Is Diagnosed
Part of what makes ALS so frustrating is that no single test confirms it. Diagnosis still relies on clinical evaluation: a neurologist looking for signs that both upper motor neurons (in the brain) and lower motor neurons (in the spinal cord) are deteriorating, and that symptoms are progressing over time. Electrical tests of muscle activity can support the clinical picture by revealing nerve damage that isn’t yet visible on exam.
The diagnostic criteria have evolved to catch the disease earlier. Older frameworks required high levels of certainty and spread across multiple body regions before a firm diagnosis could be made. Newer criteria have loosened those requirements, integrating electrical test results more directly and recognizing subtle signs like muscle twitching as meaningful evidence. Earlier diagnosis matters because it gets patients into multidisciplinary care sooner and makes them eligible for clinical trials at a stage when interventions have the best chance of making a difference.
The Realistic Outlook
ALS affects roughly 5.5 to 9.9 people per 100,000 in the United States, depending on the counting method, with CDC estimates suggesting about 25,000 Americans living with the disease at any given time. For most of them, available treatments offer months, not years, of additional time. The drugs that exist today slow the decline rather than halt it.
The shift toward genetically targeted therapies is real progress, but it applies to a small fraction of patients so far. For the majority with no identifiable genetic mutation, treatment remains focused on managing symptoms, maintaining function as long as possible, and preserving quality of life through coordinated care. A cure would require either preventing motor neuron death entirely or regenerating neurons that have already been lost, and neither is within reach yet. What is changing, gradually, is the precision with which researchers can identify and attack specific disease mechanisms, one genetic subtype at a time.